p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.
about
Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer.TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study.Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy.Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review.Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies.Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters.Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen.Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasisPrognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients.Preoperative Lymphocyte-Monocyte Ratio Is a Predictor of Suboptimal Cytoreduction in Stage III-IV Epithelial Ovarian Cancer
P2860
Q33249461-88A90438-260B-4DE8-A98B-3383BDE7AAC8Q33317044-994697A7-B7D8-41AA-A599-BB3DD40CE5A6Q33594110-81ED61F4-FE55-48F7-888D-9D3583F9B871Q36288013-C2727A0C-21BB-4309-A40E-1BC2DC1CE876Q36612301-6B346F97-1186-41EB-8B0C-2A5D2D386A1AQ36616161-C5B3F050-6254-4C28-BF2E-344704091FECQ36643987-9CB5FD8B-4EBE-4472-A8AE-BE5D8E3ED9FBQ36648786-FAD23411-F4DE-4834-B07F-046D18D3ED21Q36664249-BCE02B6E-9A0C-4B92-901A-194BE0467817Q36740653-93662B07-6D1F-4AB4-86DA-6D9D27B5E333Q37290454-7B0D14CF-F22F-4E47-A557-17CAA8CA6EB3
P2860
p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
p53 overexpression is associat ...... hemotherapy in ovarian cancer.
@ast
p53 overexpression is associat ...... hemotherapy in ovarian cancer.
@en
type
label
p53 overexpression is associat ...... hemotherapy in ovarian cancer.
@ast
p53 overexpression is associat ...... hemotherapy in ovarian cancer.
@en
prefLabel
p53 overexpression is associat ...... hemotherapy in ovarian cancer.
@ast
p53 overexpression is associat ...... hemotherapy in ovarian cancer.
@en
P2093
P2860
P921
P356
P1476
p53 overexpression is associat ...... chemotherapy in ovarian cancer
@en
P2093
Benedetti-Panici P
De Pasqua A
Maneschi F
Mottolese M
Salerno MG
P2860
P2888
P304
P356
10.1038/SJ.BJC.6690756
P407
P50
P577
1999-10-01T00:00:00Z